copy and nasal wash specimens from patient 4 also were negative for such antigens on laboratory testing. This underscores the limitations of current testing and that the sensitivity of pandemic (H1N1) 2009 diagnostic testing remains poor and needs further improvement. Thus, in patients suspected of having pandemic (H1N1) 2009 or in those who are critically ill, lower tract respiratory specimens should tested to improve diagnostic sensitivity, and clinicians should consider using immunoassay and culture methods.
All 4 patients described in this case series had viral isolates containing H275Y mutation in the neuraminidase gene of pandemic (H1N1) 2009 virus, which is specifi cally associated with high-level resistance to oseltamivir. Increasing data show that immunocompromised patients are at increased risk for development of drug-resistant infl uenza infections after oseltamivir prophylaxis or while receiving oseltamivir treatment (6) . Fortunately, this resistance trait remains rare.
Existing evidence suggests oseltamivir-resistant pandemic (H1N1) 2009 virus is stable and retains similar transmissibility and virulence as the wild-type virus (7). Therefore, in immunosuppressed patients, in which the infl uenza mortality rate is high, clinicians should also suspect drug-resistant infl uenza infection if the patient does not improve. Before she died of underlying hematologic illness, patient 2 clinically improved after treatment with intravenous zanamivir (obtained through an emergency application for an investigational-new drug). As reported in other studies, pandemic (H1N1) 2009 virus was found in her nasal washes, 1 week after she received zanamivir for 10 days (8) .
Some data suggest that pandemic (H1N1) 2009 virus has a predilection to affect the lower respiratory tract and is associated with more illness and death than is seasonal infl uenza (9). All 4 case-patients with in this series developed dyspnea, and 3 of the 4 ultimately died of refractory respiratory failure. Our observations suggest that oseltamivir-resistant pandemic (H1N1) 2009 virus is also associated with poor prognosis and may retain the same tropism for lower respiratory tract involvement as wild type.
These case-patients illustrated the complexity of the diagnosis and management of such infections in hospitalized immunocompromised patients. Figure, Several hypotheses have been proposed regarding the pathogenesis of infl uenza-associated acute encephalopathy (IAAE) (2): the most straightforward is that it is caused by viral infection of the central nervous system. The isolation of infl uenza virus from the CSF of living patients (3) (or its detection by RT-PCR) and from brain tissue of patients who have died (4) supports this hypothesis. More frequently, however, infl uenza virus has not been detected in the CSF or brains of affected patients despite thorough attempts. Thus, other possible methods for the assessing the pathogenesis of IAAE have been proposed: elevated concentrations of several cytokines such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and soluble TNF receptor-1; or determination of renal and hepatic dysfunction (2) . Although IAAE in adults and children was reported during the pandemic (H1N1) 2009 pandemic (1, (5) (6) (7) (8) , this virus was not detectedby virus isolation or RT-PCR in CSF and brain tissue of these patients. The virus was detected in CSF of an infant 3 months of age with IAAE (8); however, the virus may have been found in CSF because of the presence of blood from a traumatic lumbar puncture.
The absence of pleocytosis and the normal protein and glucose levels in CSF from the patient described here were noteworthy. Previous reports showed that leukocyte counts within normal limits (70%-90%) were found in CSF of patients with IAAE and seasonal infl uenza infection (9, 10) . Recent publications on IAAE and concurrent pandemic (H1N1) 2009 virus infection also reported no increase in CSF leukocyte count and protein level (1, 5, 7) . Therefore, absence of CSF pleocytosis and protein levels within normal limits are common with IAAE.
The diagnosis of IAAE in the patient reported here is probable, based on positive real-time RT-PCR results from CSF examination and brain MRI fi ndings. However, some limitations should be mentioned. First, a positive RT-PCR result could have resulted from contamination associated with clinical procedures and laboratory assays. Nonetheless, we believe that the lumbar puncture was done aseptically and that the real-time RT-PCR performed in the hospital's clinical microbiologic laboratory was reliable. Second, the brain MRI fi ndings were also nonspecifi c andcould be associ- However, 3 days after drug treatment was suspended, the child had a relapse and exhibited fever, cough, and mild respiratory distress. The patient had fi ne crackles in the left posterior basal lung, normal oxygen saturation, and an infi ltrate in the left basal lung, observed on chest radiograph. Infection with pandemic (H1N1) 2009 virus was confi rmed. He was then transferred to an isolated ward of the pediatric department, and oseltamivir treatment was again initiated and dosages of immunosuppressive drugs were reduced. However, no clinical or virologic responses were observed during the 3 weeks of drug administration.
Over the next month, the oral dosage of oseltamivir was increased twice, without substantial effects on clinical course and viral clearance of the infection (Figure) . Because of persistence of infection, the viral neuraminidase gene was sequenced, which showed the H275Y mutation (1). We immediately requested zanamivir aqueous solution from GlaxoSmithKline (Brentford, UK), and, after the approval of the hospital's ethics committee and parents' consent were obtained, nebulized treatment was carried out for 10 days. Fever and respiratory symptoms and signs resolved after 6 days of treatment and progressive real-time PCR gave negative results. Moreover, at the end of the treatment period, chest radiograph did not show abnormal fi ndings, and results of a hemagglutination-inhibition assay were positive for infl uenza. No zanamivirrelated adverse events were observed, except for a mild bronchospasm that responded to albuterol.
Another notable point is that the clinical course of the disease was not severe, although the child was immunocompromised and the infection persisted for almost 2 months. However,
